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Background: Ostructive	sleep	apnea	(OSA)	is	an	independent	risk	factor	for	the	devel-
opment of cardiovascular events. Platelet activation and inflammation are the mecha-
nisms	involved	in	the	association	between	OSA	and	cardiovascular	disease	(CVD).	The	
markers	of	platelet	activation	and	inflammation	are	the	mean	platelet	volume	(MPV),	
platelet-	lymphocyte	ratio	(PLR),	red	cell	distribution	width	(RDW),	neutrophil-	lympho-
cyte	ratio	(NLR).	We	aimed	to	define	the	association	of	NLR,	PLR,	RDW,	and	MPV	with	
the	severity	of	disease	and	the	presence	of	CVD.
Methods: This study consisted of 300 patients who were admitted to the sleep labora-
tory.	 The	 patients	 were	 classified	 according	 to	 their	 apnea-	 hypopnea	 index	 (AHI)	
scores	as	OSA	negative	(Group	A:	AHI<5),	mild	(Group	B:	AHI:	5-	15),	moderate	(Group	
C:	AHI=15-	30),	and	severe	OSA	(Group	D:	AHI	>30).
Results: There	were	no	significant	differences	in	the	NLR,	PLR,	and	MPV	among	the	
groups (P>.05);	only	RDW	differed	significantly	(P=.04).	RDW	was	significantly	higher	
in	patients	with	than	without	risk	factors	for	CVD	[15.6%	(15.4-	15.7)	vs	15.3%	(15.1-	
15.3),	respectively;	P=.02].
Conclusions: NLR,	PLR,	MPV,	and	RDW	are	widely	available	and	easily	obtained	from	
a	routinely	performed	hemogram.	Among	these	laboratory	parameters,	only	RDW	can	
demonstrate	 the	 reverse	 consequences	 of	 OSA-	associated	 comorbidities,	 because	
vascular damage due to systemic inflammation is an important underlying mechanism 
in	these	diseases.	RDW	might	be	used	as	a	marker	of	the	response	and	patient	compli-
ance with continuous positive airway pressure treatment.
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1  | INTRODUCTION
Obstructive	sleep	apnea	(OSA)	is	characterized	by	the	occurrence	of	
daytime sleepiness, loud snoring, witnessed breathing interruptions 
or	awakenings	due	to	gasping	or	choking	in	the	presence	of	at	 least	
five obstructive respiratory events (apneas, hypopneas, or respira-
tory	 related	 arousals)	 per	 hour	 of	 sleep	 collapse.1 The presence of 
15	 or	more	 obstructive	 respiratory	 events	 per	 hour	 of	 sleep	 in	 the	
absence sleep related symptoms is also sufficient for the diagnosis 
of	OSA.	OSA	is	known	to	be	associated	with	cardiovascular	morbid-
ity and mortality.2	OSA	 increases	 the	 risk	of	cardiovascular	diseases	
(CVD)	 including	 hypertension,	 heart	 failure,	 arrhythmias,	 and	 coro-
nary artery diseases.3	The	pathogenesis	 is	 likely	 to	be	multifactorial	
process, including sympathetic nervous system excitation, vascular 
endothelial dysfunction, oxidative stress and inflammation.4 Recurrent 
pharyngeal collapse during sleep can lead to repetitive sequences of 
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hypoxia- reoxygenation, which induce activation of the proinflamma-
tory	factors	IL-	6,	C-	reactive	protein	(CRP)	and	TNF-	α.5 Inflammation 
is one of the fundamental factors contributing to the onset and pro-
gression of atherosclerosis.6	Significant	roles	of	leukocytes	in	athero-
thrombosis	 are	 already	 known.7 Recently, neutrophil- to- lymphocyte 
ratios	(NLR)	and	platelet-	to-	lymphocyte	ratios	(PLR)	have	emerged	as	
potential	new	biomarkers	that	indicate	the	presence	of	inflammation.	
And	also,	they	can	single	out	individuals	at	risk	for	future	cardiovas-
cular events.8,9
Low level systemic inflammation and hypercoagulability have been 
associated	with	OSA	 and	 coranary	 artery	 disease	 (CAD).10 Platelets 
exhibit	a	crucial	 linkage	between	thrombosis,	 inflammation,	and	ath-
erogenesis by assembling to sites of vascular damage and inflamma-
tion.	Mean	platelet	volume	(MPV)	has	been	shown	to	be	indicator	of	
platelet activation.11	And	also,	red	blood	cell	distribution	width	(RDW)	
which	is	a	numerical	measure	of	the	size	variability	of	circulating	eryth-
rocytes, increases platelet activation. It was shown to be a strong inde-
pendent predictor of morbidity and mortality in patients with chronic 
heart failure and in patients with coronary artery disease.12
Several studies have examined the relationship between PLR and 
RDW,	 NLR	 and	 RDW,	MPV	 and	 RDW	 separately	 in	 OSA	 patients.	
However,	the	comparison	between	all	of	these	parameters	have	not	
been determined in the same patient group to date. In this study, we 
analyzed	 the	 association	 of	 PLR,	NLR,	MPV,	 and	 RDW	 all	 together	
with the severity of the disease and the presence of cardiovascular 
diseases	in	patients	with	OSA.
2  | MATERIALS AND METHODS
This study consisted of 300 patients who were admitted to the sleep 
laboratory	of	our	hospital	between	February	2013	and	October	2014.	
Overnight	 polysomnography	 (Compumedics	 E	 series,	 Melbourne,	
Australia)	was	performed	for	all	patients	recording	electroencephalo-
gram, electrooculogram, submental electromyogram, bilateral anterior 
tibial electromyogram, electrocardiogram, chest and abdominal wall 
movement by inductance plethysmography, airflow measured by a 
nasal pressure transducer and supplemented by an oral thermister 
and finger pulse oximetry, snoring microphone and video monitoring 
using an infrared video camera. The recordings were scored accord-
ing	 to	 the	 standard	 American	 Academy	 of	 Sleep	Medicine	 (AASM)	
Task	Force	Criteria.13	Apnea	was	defined	as	a	≥90%	decrease	in	the	
airflow amplitude persisting for at least 10 seconds relative to the 
baseline	 amplitude.	 Hypopnea	 was	 defined	 as	 a	 ≥50%	 decrease	 in	
the airflow amplitude relative to the baseline values associated with 
a	 ≥3%	oxygen	 desaturation	 or	 arousal	 from	 sleep,	 all	 persisting	 for	
at	least	10	seconds.	The	apnea	hypopnea	index	(AHI)	was	calculated	
as the number of apneic plus hypopneic episodes per hour of sleep. 
Sleepiness	was	assessed	by	Epworth	sleepiness	scale	 (ESS)	for	each	
patient.	We	 considered	10	 the	 normal	 limit	 of	 ESS,	 as	 stated	 in	 its	
original version.14	The	patients	were	classified	according	to	their	AHI	
as	follows:	OSA	negative	(Group	A:	AHI<5),	mild	(Group	B:	AHI:5-	15),	
moderate	OSA	 (Group	C:	 AHI:	 15-	30)	 and	 severe	OSAS	 (Group	D:	
AHI>30).	 The	 oxygen	 desaturation	 index	 (ODI)	 was	 defined	 as	 the	
total number of measurements of oxyhemoglobin desaturation of 
≥4%	within	≥10	seconds	to	<3	minutes	from	the	baseline,	divided	by	
the total sleep time.
Exclusion criteria were as follows: psychiatric causes of sleep 
disorder, central sleep apnea, use of sedatives and muscle relaxants, 
narcolepsy,	age	<18	years,	liver	or	kidney	disease,	chronic	alcoholism,	
malignacy, hyperthyroidism or hypothyroidism, inflammatory bowel 
disease, inflammatory connective tissue disorders, asthma, history of 
recent	blood	transfusion	(within	2	weeks)	and	hematologic	disorders	
such	as	leukemia,	anemia,	or	myelodysplastic	syndrome.
Demographic characteristics such as age, sex, and body mass 
index	(BMI)	were	recorded.	Cigarette	smoking	status,	previous	history	
of	chronic	diseases,	drugs,	and	habits	were	obtained	by	a	standardized	
questionnaire before the sleep study. The presence of diabetes melli-
tus	(DM),	hypertension	(HT),	or	a	smoking	history	was	accepted	as	a	
cardiovascular	risk	factor.	DM	was	defined	as	the	patient	having	been	
informed of this diagnosis by a physician before admission or current 
treatment with hypoglycemic therapy (dietary treatment, oral antidia-
betic	agents,	or	insulin).	HT	was	defined	as	a	known	elevation	of	blood	
pressure on at least two separate occasions according to the medical 
history or the use of antihypertensive medications in a patient with 
known	controlled	hypertension.	CVD	referred	only	to	the	presence	of	
heart	failure,	coronary	artery	disease,	or	arrhythmia.	Diagnosis	of	CVD	
was made by an expert cardiologist and the patients were being med-
ically treated with one or more than one antiaggregants, antiischemic 
agents,	 beta	 blockers,	 angiotensin-	converting	 enzyme	 (ACE)	 inhibi-
tors,	angiotensin-	receptor	blockers	(ARB),	or	calcium	antagonists.
The	RDW,	MPV,	platelet,	neutrophil,	and	lymphocyte	counts	were	
determined	using	the	Abbott	Cell-	Dyne	3700	Hematology	Analyzer,	
as one part of a hemogram. The NLR and PLR were obtained from the 
absolute neutrophil and platelet counts, respectively, divided by the 
absolute lymphocyte counts.
2.1 | Statistical analysis
All	results	were	expressed	as	the	mean±standard	deviation.	All	analy-
ses	were	done	using	 the	Statistical	Package	 for	 the	Social	 Sciences	
(SPSS),	V.	15.0	(SPSS,	Chiacago,	IL,	USA).	A	power	analysis	was	con-
ducted to determine the number of participants needed in the study. 
The α	for	the	ANOVA	will	be	set	at	<.012.	The	inclusion	of	minimum	
25	 participants	 per	 group	 provided	 95%	 power	 for	 detecting	 dif-
ferences	 in	 plasma	RDW	 levels.	 The	 chi-	squared	 test	was	 used	 for	
the	 comparison	 of	 qualitative	 variables.	 For	 quantitative	 variables,	
Kruskal–Wallis	test	was	used	when	the	number	of	groups	exceeded	
two	and	but	the	data	did	not	fit	a	normal	distribution.	Analysis	of	vari-
ance was used to compare more than two groups when the data fit the 
normal	distribution.	When	there	were	significant	differences	among	
the groups, Mann–Whitney	U test was used for multiple comparisons. 
The Spearman’s test or Pearson’s correlation was used to determine 
the	relationships	between	variables.	To	establish	RDW	cut-	off	value	
to	 distinguish	 between	 patients	 with	 or	 without	 CVD	 risk	 factors,	
receiver	 operating	 characteristic	 (ROC)	 analysis	was	performed	 and	
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areas	under	curve	were	calculated.	A	P	value	of	<.05	was	considered	
satatistically significant.
3  | RESULTS
The clinical characteristics and laboratory parameters of the study 
population	 are	 summarized	 in	 Table	1.	 According	 to	 their	 AHI,	
patients	were	divided	into	Group	A	(n=52;	17.3%),	Group	B	(n=53;	
17.6%),	Group	C	 (n=65;	21.6%)	and	Group	D	 (n=130;	43.3%).	The	
mean	age	of	the	patients	was	47.6±11.8	years	and	75.6%	(227)	were	
male.	Age	and	BMI	gradually	but	 significantly	 increased	 in	parallel	
with	the	severity	of	OSA	which	was	statistically	significant	(P<.01).	
The	 rates	 of	 DM	 and	 HT	 were	 significantly	 different	 among	 the	
groups (P<.01).	And	also,	the	rates	of	patients	with	CVD	risk	factors	
were significantly different among the groups (P=.03).	 However,	
Group	 D	 had	 a	 higher	 prevalence	 of	 CVD	 than	 the	 other	 three	
groups, the difference was not statistically significant. The use of 
ARBs/ACE	inhibitors	was	significantly	higher	in	Groups	C	(35%)	and	
D	(38%)	than	in	Groups	A	(13%)	and	B	(19%;	P<.01).	The	patients	in	
Group	A	used	calcium	antagonists	significantly	less	frequently	than	
the other groups (P=.02).	There	was	no	significant	difference	among	
the	groups	with	respect	to	smoking.	Additionally,	the	mean	values	of	
platelet,	lymphocyte,	neutrrophil	counts;	NLR;	PLR	and	MPV	did	not	
show statistically significant levels among the four groups (P>.05).	
Only	 RDW	 differed	 significantly	 among	 the	 four	 groups	 (P=.04).	
RDW	showed	a	significant	 increase	 in	parallel	with	the	severity	of	
OSAS.
The polsomnographic study results are presented in Table 2. The 
distribution	of	sleep	stages,	AHI,	mean	and	minimum	oxygen	satura-
tion, ODI were significantly different among the groups (P<.01).	All	the	
patients	had	ESS	 score	<10	and	 there	was	no	 significant	difference	
among the groups with respect to ESS (P=.028).
We	also	noted	the	correlations	between	polysomnographic	results	
and laboratory parameters. Spearman correlation analysis showed a 
significant	 correlation	 only	 between	 RDW	 and	 polysomnographic	
parameters.	The	MPV,	NLR	and	PLR	were	not	significantly	correlated	
with	 the	 polysomnographic	 parameters.	 RDW	 was	 positively	 cor-
related	with	the	AHI	and	ODI	but	negatively	correlated	with	the	mean	
oxygen saturation (P<.05;	Table	3).
There were no significant differences in the platelet, lymphocyte, 
neutrophil	counts;	NLR;	PLR;	MPV	and	RDW	between	patients	with	
OSA	 with	 vs	 without	 CVD	 (P>.05).	 RDW	 values	 were	 significantly	
higher	in	patients	with	than	without	CVD	risk	factors	(P=.02).
TABLE  1 Demographic and laboratory findings of the study group
Group A control group 
(n=52)
Group B mild OSA 
(n=53)
Group C moderate 
OSA (n=65)
Group D severe  
OSA (n=130) P
Age	(y) 41±12 43±10 50±11 51±11 <.01
Gender,	Male	n	(%) 35	(67%) 44	(83%) 47	(72%) 101	(78%) .379
BMI	(kg/m2) 29±4.3 29±4.5 31.3±4.3 34±6 <.01
Risk	factors	for	CVD 35	(67%) 34	(64) 52(80%) 102(78%) .03
Hypertension 11	(21%) 14	(26%) 29	(45%) 59	(45%) <.01
Diabetes mellitus 2	(4%) 6	(11%) 11	(%17) 35	(27%) <.01
Smoking 29	(56%) 29	(55%) 26	(40%) 61(47%) .188
CVD 8	(15%) 9	(17%) 8	(12%) 26	(%20) .450
Prehospital medications, n (%)
Β	blockers 10	(19%) 8	(15%) 13	(20%) 27	(21%) .587
ARBs/ACE	inhibitors 7	(13%) 10	(19%) 23	(35%) 50	(38%) <.01
Calcium	antagonists 4	(7.6%) 8	(15%) 11	(17%) 28	(%21) .02
Antiplatelet	agents
Laboratory findings
Platelets (×103/μL) 259±62 263±60 260±57 272±62 .621
Lymphocytes (×103/μL) 2.6±0.6 2.5±0.8 2.6±0.7 2.7±0.6 .701
Neutrophil (×103/μL) 4.47±1.2 4.6±1.4 4.6±1.5 4.7±1.4 .730
PLR 102±28.5 108±42 105±36 105±31 .857
NLR 1.9±1.03 2±1 1.8±1 1.8±0.7 .183
MPV,	fL 7.3±1.3 7.2±1 7.4±1 7.5±1.1 .348
RDW	(%) 15.2±1.02 15.6±1.06 15.7±1.2 16±1.2 .04
BMI,	Body	Mass	Index;	CVD,	Cardiovascular	disease;	ACE,	angiotensin-	converting	enzyme;	ARB,	Angiotensin	receptor	blocker;	PLR,	Platelet-	lymphocyte	
ratio;	NLR,	neutrophil-	lymphocyte	ratio;	MPV,	mean	platelet	volume;	fL,	femtoliters;	RDW,	red	cell	distribution	width.
Significant values are given in bold.
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We	 used	 ROC	 analysis	 to	 determine	 the	 cut-	off	 value	 of	 RDW	
(>16)	to	demonstrate	the	presence	of	CVD	risk	factors.	The	analysis	
revealed	a	sensitivity	of	34.5%,	specificity	of	84.4%	and	area	under	the	
ROC	curve	of	0.584.	(CI=0.526-	0.640,	P<.05;	Figure	1).
4  | DISCUSSION
Ostructive sleep apnea has been associated with many comorbidities 
such as cardiovascular diseases, pulmonary diseases, endocrine dys-
functions	and	neuropsychiatric	problems.	Although	the	exact	mecha-
nism underlying these problems remains unclear, chronic inflamma-
tion has been implicated in their pathogenesis.15 To address this issue, 
we	analyzed	several	inflammatory	factors	such	as	PLR,	NLR,	MPV,	and	
RDW	levels	in	patients	with	OSA.	And	also	we	evaluated	the	associa-
tion	of	these	markers	with	the	severity	of	the	disease	and	the	pres-
ence	 of	 cardiovascular	 diseases	 in	 patients	with	OSA.	Detection	 of	
inflammatory	factors	in	OSA	patients	may	help	us	to	predict	the	risk	
and severity of these comorbid diseases.
Neutrophil-	lymphocyte	ratio	is	a	new	biomarker	which	indicates	
the presence of inflammation. Evaluation of the NLR in the diseases 
may help us to predict the progression and prognosis of the dis-
ease	 processes.	 Various	 studies	 have	 demonstrated	 the	 correlation	
between the NLR and lung cancer, pneumonia and tuberculosis.16-18 
Gunay	and	associates	indicated	that	NLR	was	higher	in	patients	with	
acute	exacerbation	of	chronic	obstructive	pulmonary	disease	(COPD)	
than	in	patients	with	stable	COPD	and	healthy	controls.19	However,	in	
our	study	there	was	no	significant	difference	among	the	OSA	groups	
with	 respect	 to	NLR.	And	also,	NLR	was	not	significantly	correlated	
with polysomnographic parameters. This result is in agreement with 
Korkmaz	 and	 associates,	who	 found	 no	 difference	 in	NLR	 between	
patients	with	and	without	OSA.20
Platelet-	lymphocyte	 ratio,	 another	 recent	 novel	 biomarker,	
has been proved to be both sensitive and reliable for evaluation 
of inflammation. Sunbul and associates found that increased PLR 
was associated with non- dipper state in hypertensive patients.21 
Koseoglu and associates reported that PLR is strongly associated 
with	the	severity	of	OSA	and	CVD	in	patients	with	OSA.8	However,	
TABLE  2 Polysomnographic findings of the study group
Group A control group 
(n=52)
Group B mild OSA 
(n=53)
Group C moderate OSA 
(n=65)
Group D severe OSA 
(n=130) P
Stage	1	(%) 5.1±4.3 3.8±2.6 4.6±4.1 4.1±4.3 .31
Stage	2	(%) 53±10 51±12.3 56±12 68±15 <.01
Stage	3	(%) 24±8 26±10 24±10 17±12 <.01
REM	(%) 18±8 18.6±6 15.1±6.6 12±7 <.01
SE	(%) 83±13 85±12 84±11.8 85±13 .353
AHI	events/h 2.2±1.5 10.1±2.1 23±5.1 60±24 <.01
Mean O2	sat	(%) 110±117 92±4.1 90±3 86±6 <.01
Minimum O2 sat 89±4.35 85±3 80±6.6 73±10 <.01
ODI 2.06±1.5 9.5±3 21±5 57±23 <.01
ESS 5	(0-	15) 8	(0-	18) 7	(0-	18) 7	(0-	19) .028
REM,	Rapid	eye	movement;	SE,	Sleep	efficiency;	AHI,	Apnea-	hypopnea	index;	sat,	saturation;	ODI,	oxygen	desaturation	ındex;	ESS,	Epworth	sleepiness	
scale.
Significant values are given in bold.
TABLE  3 Correlation	between	polysomnographic	parameters	and	
RDW
RDW
r P
AHI	events/h .123 .033
Mean O2	sat	(%) −.118 .047
ODI .119 .038
AHI,	 Apnea-	hypopnea	 index;	 sat,	 saturation;	 ODI,	 oxygen	 desaturation	
ındex.
Significant values are given in bold.
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in	our	study,	PLR	was	similar	between	the	OSA	and	control	groups.	
There	was	no	significant	difference	in	the	PLR	in	patients	with	OSA	
with	vs	without	CVD.
Chronic	 inflammation,	 hypoxia,	 and	 sympathetic	overactivity	 are	
associated	with	the	pathogenesis	of	platelet	activation	in	OSA.5	MPV	
is	another	marker	of	platelet	activation.22 Recent reports have demon-
strated	that	MPV	is	significantly	higher	in	patients	with	than	without	
OSA.8,23	The	 increased	cardiovascular	risk	 in	patients	with	OSA	may	
also	be	 linked	to	abnormalities	of	coagulation	and	excessive	platelet	
activation.24 In our study, we did not find any significant correlation 
between	MPV	and	the	severity	of	OSA.	Our	result	is	in	agreement	with	
that	of	Kurt	and	associates,	who	reported	that	the	severity	of	OSA	was	
not	correlated	with	MPV.4
Inflammation has also the capacity to shorten red blood cell sur-
vival.25	Inflammation	has	been	proposed	as	a	key	point	in	the	asso-
ciation	of	RDW	with	 the	cardiovascular	and	pulmonary	diseases.26 
Ozsu	 and	 associates	 have	 demonstrated	 that	 OSA	 patients	 have	
elevated	levels	of	RDW	compared	to	controls	but	they	did	not	find	
any	association	between	the	severity	of	OSA	and	RDW.27	However,	
in	 our	 study,	 RDW	 differed	 significantly	 among	 the	 OSA	 groups.	
Moreover, there was a significant correlation between the level of 
RDW	 and	 the	 severity	 of	OSA.	A	 high	 level	 of	 RDW	 in	OSA	may	
be caused by numerous factors including inflammation, age, and 
obesity. In addition, in our study, there was a positive correlation 
between	the	severity	of	OSA	and	age	and	BMI.	And	also,	we	found	
a	significant	positive	correlation	between	the	level	of	RDW	and	AHI	
and	ODI.	All	these	results	suggest	that	RDW	may	play	a	role	in	the	
pathogenesis	of	OSA.
An	elevated	RDW	may	be	an	 indicator	of	underlying	 inflamma-
tion	 in	 OSA.	 RDW	 can	 demonstrate	 the	 reverse	 consequences	 of	
OSA-	associated	comorbidities,	because	vascular	damage	due	to	sys-
temic inflammation is an important underlying mechanism in these 
diseases.	Hypoxemia,	inflammation,	increased	heart	rate,	and	blood	
pressure	 in	OSA	 lead	 to	cardiovascular	morbidity.28	We	 found	 that	
RDW	values	were	significantly	higher	in	patients	with	than	without	
CVD	risk	factors.	An	elevated	RDW	may	also	be	proposed	as	a	simple	
and	diagnostic	 tool	 for	monitoring	patients	with	OSA,	 those	espe-
cially with cardiovascular disease. To address this issue, we deter-
mined	the	cut-	off	value	of	RDW	(>16)	to	demonstrate	the	presence	
of	CVD	risk	factors.
Taken	together,	our	results	indicate	that	among	these	laboratory	
parameters,	only	RDW	can	be	used	as	an	inexpensive	tool	for	triag-
ing	OSA	patients	for	polysomnographic	evaluation	in	sleep	laborato-
ries and these patients could able to reach earlier treatment options. 
And	also,	RDW	might	also	be	used	as	a	marker	of	the	response	and	
patient compliance with continuous positive airway pressure treat-
ment.	However,	 there	 are	 some	 limitations	 of	 our	 study	 that	 have	
to	be	mentioned.	We	did	not	follow	the	patients	prospectively	and	
did not investigate the effect of continuous positive airway pres-
sure	 treatment	 on	 RDW.	 In	 this	 context,	 prospective,	 randomized,	
controlled studies before and after continuous positive airway pres-
sure treatment are needed to assess the association between these 
parameters	and	OSA.
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